| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005646 | Clinical Therapeutics | 2005 | 13 Pages |
Abstract
Use of pramlintide in addition to insulin1026 in patients with type 1 and type 2 diabetes was associated with modest reductions in HbA1c. The primary adverse effects of pramlintide therapy were nausea and hypoglycemia.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
PharmD, BCPS, CDE Ryan, DVM, PhD Jobe, PharmD, BCPS Martin,